Proton beam takes aim at returning throat cancer
NCT ID NCT07412314
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a precise type of radiation called proton therapy for people whose nasopharyngeal cancer has come back. The goal is to see if it can control the cancer while causing fewer severe side effects than standard treatments. About 52 adults with recurrent, non-spreading cancer will take part. Researchers will track serious complications and how long participants live.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 52 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2025
- Expected to finish
-
Mar 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Non-metastatic squamous cell carcinoma of the nasopharynx with biopsy confirmation, at stage ≥ T2b and/or with positive lymph nodes, (2) Pathological type WHO I-III 2. PS score (according to Eastern Cooperative Oncology Group (ECOG) standard) 0-1. Age ≥ 18 years. 3. Expected survival period ≥ 6 months 4. Before treatment, evaluate the tumor range and size of the patient. 5. Nutritional and general physical condition must be able to tolerate the recommended radiotherapy and chemotherapy. Exclusion Criteria: 1. Evidence of distant metastasis in stage IVc 2. Patients with isolated recurrence of cervical lymph nodes; 3. Patients have participated in other interventional trials for tumors 4. Having suffered from other malignant tumors within 5 years (excluding melanoma skin cancer) or tumors originating from the head and neck region Untreated active infections
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Recurrent nasopharyngeal carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Guangzhou Concord Cancer Center
RECRUITINGGuangzhou, Guangdong, China
-
Guangzhou concord cancer center
RECRUITINGGuanzhou, Guangzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy plus chemo shows promise for Tough-to-Treat nasopharyngeal cancer
- Immunotherapy boost may improve outcomes in returning throat cancer
- New surgery technique could improve survival in recurrent throat cancer
- Drug combo targets rare cancers in early trial
- Immune booster: donor NK cells aim to cut cancer recurrence
- Double immunotherapy may keep nasopharyngeal cancer at bay